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Abstract
Background. In cases of multiple myeloma, palliative care includes patients who still undergo active
oncological treatment and those who have discontinued it. The aim of the research is to present the
difficulties which doctors of palliative care and others taking care of patients with multiple myeloma may
face.
Material and methods. The trial included patients of home hospice care and the patients of a Palliative
Care Ward. Retrospective analysis based on medical documentation was applied and, in patients that were
still on treatment, prospective observation was conducted.
Results. The analysis included four patients on chemotherapy and two patients for whom intensive onco-
logical treatment had been discontinued. The most frequent symptoms were afflictions connected to bone
pain. These were often accompanied by secondary neurological symptoms of pathological bone fractures or
compressions caused directly by the neoplastic tumour and symptoms of peripheral neuropathy. Secondary
nephropathy (myelomic kidney) and a tendency to hypercalcaemia occurred. Various symptoms of blood
hyperviscosity syndrome (dysfunctions of organs: kidneys, heart; bleeding gums and nose) were observed.
Additionally during palliative care, it was essential to notice and counteract disease aggravations.
Conclusion. Patients with multiple myeloma constitute a great challenge in palliative care due to the
changeable clinical course of the disease, repetitive relapses and remissions. Numerous symptoms of the
disease require continuous observation and the proper treatment, which demonstrates that simultaneous
multi-specialist care is essential.
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Introduction
Plasmocytoma (multiple myeloma) belongs to a
group of diseases called monoclonal gammopathy.
It is a neoplasm of B lymphocytes. It is characterized
by the proliferation of atopic plasmocytes, most of-
ten in flat and long bones that produce monoclonal
immunoglobin: M-protein (class IgG 55%, IgA 30%).
The urine of patients often contains immunoglobin
light chains (Bence-Jones protein). Plasmocytoma is
a disease of the haematogenic system and it consti-
tutes ~1% of all neoplasms and ~13 % of the neo-
plasms of the haematogenic system [1–6].
The symptoms of multiple myeloma are connect-
ed to the development of neoplastic cells and the
activity of cytokines and the proteins they produce.
The patients suffer from many different afflictions
in the course of the disease. The most frequent symp-
tom is bone pain (60% of cases). This mainly con-
cerns the spine, flat bones (pelvis, ribs, skull) and
long bones. The pain is caused by osteolytic chang-
es and the pathological fractures (compressive ver-
tebral fractures or pathological fractures of long
bones). Secondary to bone deformations, neurolog-
ical symptoms may appear as a result of spinal cord
compression, spinal nerve root compression or cra-
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nial nerve compression. These symptoms may also
be caused by the direct compression of nerve struc-
tures by a neoplastic tumour. In the case of very
advanced changes, paresis or paralysis of limbs may
be observed. As far as neurological ailments are con-
cerned, we may observe symptoms of peripheral
neuropathy, usually of the mixed type (sensorimo-
tor). The symptoms are usually a result of demyeli-
nation and degeneration of nerve fibres, neoplastic
invasion, amyloidosis (in the neighbourhood of
nerves or vessels responsible for vascularization of
nerves), and of the direct toxic influence of M-pro-
tein on nerve endings, which takes place in blood
hyperviscosity syndrome.
Patients with multiple myeloma often suffer from
chronic renal disease. At the moment of diagnosis,
the problem already concerns 30% of the patients.
Light chains are deposited in the kidneys and form
amyloid. Amyloid damages the kidneys and prompt
interstitial inflammatory lesions. Interstitial nephri-
tis may also be induced by the deposition of calcium
concrements in the renal tubules, and both hyper-
calcaemia and hypercalciuria are observed in some
patients.
Secondary amyloidosis and hyperuricaemia with
the precipitation of uric acid crystals may appear in the
collecting tubules. Hypercalcaemia results from hyper-
activity of osteoclasts and its symptoms may be dis-
crete and may develop slowly. The symptoms include
drowsiness, headache, orientation disorders, nausea,
vomiting, constipation, asthenia or muscular adinamia,
dysphagia, polyuria, and dehydration [1–3, 6, 7].
Deterioration in the functioning of the immuno-
logical system stems from the presence of improper
immunoglobines, which favours infections, especially
of the respiratory and urinary systems. The risk of
infection is further increased during and after che-
motherapy. In about 10% of patients with multiple
myeloma, hyperviscosity syndrome, connected to the
increased concentration of M-protein, is observed.
This mostly concerns IgA multiple myeloma because
it is mainly immunoglobin A that polymerizes and
closes microcirculatory vessels, which may contrib-
ute to a deterioration in the functions of many or-
gans. It is a cause of symptoms from the central
nervous system: drowsiness, consciousness distur-
bances, hearing deterioration, and headaches. Co-
agulation disorders cause bleeding, especially from
the nose and gums.
In 80% of cases with multiple myeloma, the pa-
tients suffer from anaemia, which is caused by the
disease itself or as a secondary effect of chemo-
therapy (myelosuppressive treatment).
The dysfunction of organs is called CRAB:
C (calcium) — increased concentration of calcium
>10 mg/dl;
R (renal) — concentration of creatinine > 2 mg/dl;
A (anaemia) — Hgb < 10 g/dl;
B (bone) — osteolysis [1, 2, 4].
Multiple myeloma may be in the shape of a sin-
gle plasmocytoma tumour and appear mainly in the
bones (4%). Only in 1–2% of cases is it located else-
where in the body [1, 5, 6]. Plasma cell leukaemia is
usually but not always seen in advanced disease,
constituting around 4% of plasmocytoma. It is diag-
nosed on the basis of improper plasmocytes in the
blood. The prognosis for the disease is pessimistic,
the course is rapid and the disease is usually accom-
panied by hepato- and splenomegalia and lymphad-
enopathy [1, 6].
Aim
The aim of this study was to present the difficul-
ties that specialists in palliative medicine and others
taking care of patients with multiple myeloma may
face. We also wanted to draw attention to the di-
versity of symptoms and a selection of the second-
ary complications that often need to be investigat-
ed by many specialists, thus demonstrating that the
treatment should be multi-dimensional.
Material and methods
The Bioethics Committee of the Collegium Medi-
cum in Bydgoszcz, gave consent to conduct the tri-
al. The analysis included patients with multiple my-
eloma who, between 2006 and 2007 were treated
by specialist in palliative medicine either in Palliative
Care Department of University Hospital or in home
care provided by the Priest Jerzy Popiełuszko Hos-
pice in Bydgoszcz. Retrospective analysis based on
the medical documentation completed during diag-
nostics, haematological treatment and palliative care
was used. In the cases of patients who were alive
during the trial, prospective observation was con-
ducted. The analysis included information about the
diagnosis, haematological treatment that had been
introduced or withdrawn, symptoms of the disease
and any clinical difficulties connected with them.
Results
The trial included six patients (Table 1). Five of
them had died before the commencement of the
trial and one of them is still being treated by
www.advpm.eu 139
Michał Graczyk et al., Problems of palliative care
a haematologist and provided with home palliative
care.
Patient 1
Patient (M): 81 years old, diagnosed with multi-
ple myeloma in November 2006. Preliminary diag-
nostics revealed compressive fracture of the verte-
bral body of L2, proliferation of plasmatic cells in
bone marrow, aleukocytosis, secondary anaemia
and chronic oesophagogastritis. The patient was
referred to the Haematology Department and in-
travenous infusion of disodium pamidronate was
given because of hypercalcaemia. Due to agranu-
locytosis, the patient was administered filgrastim,
recombinant human granulocyte-colony stimulat-
ing factor (G-CSF). Back pain decreased and the
patient was advised to wear a Jewett-type corset.
In 2007, chemotherapy according to the scheme of
MP (melphalan, prednizone) was introduced. Fol-
lowing chemotherapy (ChTH), the patient was hos-
pitalized because of bilateral pneumonia. In March
2007, ChTH was continued and the patient was
provided with home hospice care due to periodical
chronic spinal pain. Each time the patient was on
the Haematology Ward, he received a transfusion
of packed red blood cells (PRBC) and, once, he was
administered with G-CSF due to agranulocytosis.
He also suffered from bleeding from the left nose
wing and the mucous membranes of the mouth.
Those incidents led to severe anaemia and required
the transfusion of PRBC and constant administra-
tion of etamsylate. In June 2007 a colonoscopy
performed after the bleeding from the lower gas-
trointestinal tract showed a few diverticula of the
sigmoid colon and a polyp which was then removed.
The orthopaedic surgeon advised gradual discon-
tinuation of the Jawett corset and in the case of an
aggravation of the afflictions he suggested prepar-
ing a lumbar corset with laces for the patient. Dur-
ing home care, a haematologist was regularly con-
Table 1. Characteristics of patients
Patient Coexistent Bone pain Administered Bisphosphonate Clinical
(sex, age) diseases painkillers problem
Patient 1 Hypertension Yes Paracetamol Yes Mucuous
(M, 81) Secondary myocardiopathy Condition after Tramadol membrane
with mitral and aortal compressive fracture bleeding
 incompetence of L2 vertebral body Anaemia
Oesophagogastritis  Osteoarthritis
Liver cyst
Kidney cysts
Bilateral cataract
Patient 2 Hypertension Yes Paracetamol Yes Throat pain
(M, 74) A condition Condition after NSAIDs Anaemia
after heart attack compressive fracture Tramadol Ion disorders
of Th 8
Patient 3 Hypertension Yes Paracetamol Yes Upper airways
(F, 67) Nodular goitre during Condition after compressive NSAIDs infections
hypothyreosis fracture of Th12 and L3 Tramadol Otolaryngological
Chronic endogastritis Discopathy of L4 and L5 infections
A condition after cholecystectomy A condition after Anaemia
left-side fracture of ribs
Patient 4 Chronic renal disease Yes Paracetamol Yes LE paresis
(M, 67) Condition after left  Numerous osteolytic Tramadol Muscular atrophy
orchidectomy because changes in the course Anaemia
of cancer of the disease
Patient 5  (–) Yes Paracetamol Yes Anaemia
(M, 67) Osteoarthritis of spinal NSAIDs Subfebrile
kolumn Tramadol conditions
Sweating
Patient 6 Diabetes type 2 Yes Paracetamol Yes LE paresis
(F, 70) Chronic renal disease Condition after NSAIDs Anaemia
Hypertensional myocardiopathy compressive fracture Tramadol Chronic
during cardiac failure II NYHA of Th 4 and 5 Morphine renal disease
Condition after engraftment Condition after
of right hip joint endoprothesis pathological fracture
 Condition after BSOH of right radial bone
M — male; F — female; NSAIDs — non-steroidal anti-inflammatory drugs; NYHA — New York Heart Association; LE — lower extremities;
BSOH — bilateral salpingectomy, oophorectomy and hysterectomy
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sulted in order to establish further proceedings.
During the following periods of hospitalization,
a progression of secondary nephropathy was ob-
served in the patient: increasing concentration of
creatinine from 1.2 mg/dl on the day of diagnosis
to 2 mg/dl (05.2007) and finally 5.5 mg/dl during
the last stay in hospital in July 2007. Then, due to
significant anaemia (Hgb 5.2 g/dl), PRBC transfu-
sion was conducted. When the patient returned
home, repetitive bleeding from the mucous mem-
branes of the nose and rectal bleeding were ob-
served. The patient died at home on 5 August 2007.
The direct cause of death was probably related to
the severe secondary anaemia.
Patient 2
Patient (M): 74 years old with multiple myelo-
ma IgG type kappa diagnosed seven years ago.
Medical history included a compressive fracture of
the thoracic spine at Th8, secondary nephropathy,
bilateral disseminated flat and nodular solid lesions
in chest connected to the parietal pleura. Previous-
ly the patient had been treated with subsequent
cycles of chemotherapy, however in November
2006, the VMCP scheme (vincristine, melphalan,
cyclophosphamide and prednisone) was introduced,
but did not result in disease remission. The patient
underwent transfusion of leucocyte-poor irradiat-
ed PRBC because of secondary anaemia and a plas-
mapheresis was conducted twice due to a high
level of monoclonal protein. The patient was qual-
ified for further treatment with cytostatics accord-
ing to the VAD scheme (vincristine, doxorubicin
and dexamethasone). After July 2007, he was re-
ferred to home palliative care due to bone pain
and progressive asthenia. In August 2007, the pa-
tient was admitted to the Haematology Ward in
order to continue chemotherapy. Due to strong
retrosternal pain and dyspnoea, he was referred to
the Cardiology Ward and the coronarography and
a percutaneous angioplasty of the right coronary
artery were performed. At that time, probably af-
ter contrast administration, a deterioration of chron-
ic renal disease was observed. The creatinine level
increased from 1.3 mg/dl to 2.9 mg/dl (on discharge:
1.57 mg/dl). After returning home, the patient com-
plained of pains in the stomach, chest and knee
joints which were moderately controlled by trama-
dol and ketoprofen. The condition of the patient
gradually deteriorated, he accepted meals with dif-
ficulty, and the amount of liquids he was drinking
lowered significantly. In September 2007, a con-
trol examination showed an increase in the creati-
nine level to 3.49 mg/dl and electrolyte disorders
(potassium 5.64 mmol/l, sodium 119 mmol/l). Re-
gardless of intravenous treatment, no clinical im-
provement was achieved. The patient died in Sep-
tember 2007 at home, probably due to advanced
disease and chronic renal failure.
Patient 3
Patient (F): 67 years old with multiple myeloma
IgG type kappa, diagnosed in March 2006. Before
diagnosis was confirmed, she had been treated with
percutaneous vertebroplasty of Th12 with bone ce-
ment because of a compressive fracture of Th12
and L3 vertebrae. That treatment significantly di-
minished the pain. In April 2006 the diagnosis con-
firmed multiple myeloma (total protein 13.46 g/dl,
monoclonal protein 8.67 g/dl, plasmocytes in the
marrow 74.4%, osteolysis in the skull and femoral
bones) and the patient was qualified for cytostatic
treatment (VAD scheme). The chemotherapy was
complicated by bronchopneumonia in the course of
neutropenia and superficial phlebitis of the left low-
er extremity. The patient needed a wide spectrum
antibiotic, G-CSF and a transfusion of leucocyte-poor
irradiated PRBC. Then the patient was referred to
home palliative care because of bone pain resistant
to NSAIDs. Tramadol in a dose of 3 ¥ 50 mg provid-
ed the satisfactory pain relief and NSAIDs were
stopped. The patient continued chemotherapy, first
according to the VMCP scheme, then he received
cyclophosphamide and dexamethason due to leu-
copenia. Following several cycles of chemotherapy
patient was very weak and suffered from repetitive
infections of the upper airways, the middle ear and
conjunctivitis. In June 2007, the diagnosis showed
a zoster located in the underarms, along the right
costal margin. Additionally, the patient suffered from
hearing deficit of the left ear which according to
a laryngologist, was probably a result of the chemo-
therapy. Actually, apart from cytostatics adminis-
tered systematically, the patient is treated with bis-
phosphonates (due to the bone lesions and hyper-
calcaemia) and tramadol in a dose of 3 ¥ 50 mg
orally with satisfactory pain relief.
Patient 4
Patient (M): 67 years old with multiple myeloma
diagnosed in January 2007 with multiple osteolytic
lesions. The patient was qualified for chemotherapy
and he was administered with VI cycles according to
the VAD scheme. In August 2007, he was referred
for hospice home care due to pain. On admission
the patient had sense disorders in both lower ex-
www.advpm.eu 141
Michał Graczyk et al., Problems of palliative care
tremities with coexistent muscular atrophy, pains
along the spine escalating during movement and
features of cachexia. His medical history included
left-side orchidectomy because of cancer in 1991
with subsequent chemo- and radiothe-rapy, and
chronic renal disease and secondary anaemia. Due
to pain symptoms (mainly bone pain), the patient
was treated with tramadol, dexamethasone and bis-
phosphonates. In October 2007, the clinical condi-
tion of the patient suddenly deteriora-ted, the pa-
tient became weaker, with disturbed communica-
tion and difficulties in swallowing. The patient had
died before the planned additional tests could be
carried out (hypercalcaemia was suspected because
of multiple osteolytic lesions).
Patient 5
Patient (M): 68 years old with multiple myeloma
diagnosed in August 2004. At the time of diagnosis,
monoclonal IgG lambda-type proteins were observed
as well as an increased level of plasmocytes in the
marrow. Bones radiographs did not show any os-
teolytic changes, which are typical for myeloma. The
patient qualified for chemotherapy according to the
VMCP scheme. In September 2004, during the II
cycle of chemotherapy (VBAP — vincristine, carmus-
tine, doxorubicin and prednisone), antiviral drugs
were added to the treatment because of herpes. In
March 2005, after three full changeable cycles, the
patient was admitted to the Haematology Ward in
order to assess the grade of development of the
disease. A biopsy of the marrow from the sternum
provided non-guttate contents, a non-diagnostic
material. In May 2006 after trepanobiopsy of the
marrow (hypoplastic marrow) and a myelogram
(presence of 53.6% lymphoplasmatic cells and 4.8%
plasmocytes) the patient was qualified for treatment
according to the changeable scheme. Neutropaenia
and an inflammation of the deep veins of the right
leg complicated chemotherapy. In February 2007,
another trepanobiopsy was conducted. It showed
hypercellularity of the marrow, and myeloma infil-
trations (CD38+) constituted around 90% of all cells
in the represented fragment. The patient was treat-
ed with dexamethasone due to pancytopaenia. Af-
ter consultation in the Haematology Clinic of the
Collegium Medicum in Gdańsk in May 2007, the
patient was qualified for chemotherapy with thali-
domide joined with dexamethasone infusions. Due
to complications during the treatment (high fever
with chills, E.coli bacteraemia, requiring targeted
antibiotic therapy) the thalidomide treatment was
discontinued. During the stay on the Haematology
Ward in July 2007, chemotherapy according to the
MP scheme was introduced to the treatment. While
being hospitalized during the course of the disease,
the patient required several transfusions of PRBC
due to primary anaemia, as well as the administra-
tion of filgrastimes due to neutropaenia. The pa-
tient often experienced heightened body tempera-
ture (mainly subfebrile states and also fever period-
ically) and sweating. During home care the patient
exhibited a periodical exacerbation of spinal pain,
so he was administered tramadol, NSAIDs and parac-
etamol (also due to abnormal body temperature
and sweating). The patient died on 30 October 2007
in Hospice. The exact cause of death remains un-
known.
Patient 6
Patient (F): 70 years old with multiple myeloma
diagnosed in March 2005. She was qualified for
chemotherapy according to the VMCP scheme and
received the last cycle in April 2007. In May 2007,
the patient was admitted to the Neurosurgical Ward
of the University Hospital due to pathological spinal
fracture (compressive fracture of Th 4 and 5) as a
result of an injury. A computer tomography of the
spine showed a pathological mass (59 ¥ 39 mm),
which filled a significant part of the spinal channel
Th5–Th6, developing towards the chest, probably
with descending aorta invasion. The patient was
qualified for symptomatic treatment. Due to sur-
rounding chest pain and paresis of the lower ex-
tremities, the patient was referred to the Palliative
Care Ward on 15 May 2007. He also suffered from
diabetes type 2, secondary nephropathy (on admis-
sion creatinine 2.3 mg/dl), secondary anaemia and
hypertension myocardiopathy. On admission, the
patient was initially administered tramadol. How-
ever, due to the unsatisfactory pain relief, tramadol
was replaced by morphine which was gradually in-
creased to a dose of 60mg per day. Due to deteriora-
tion and chronic renal disease (a rise of creatinine
concentration to 3.9 mg/dl, hyperkaliemia: potassi-
um 6.7 mmol/l, and metabolic acidosis), the treat-
ment was changed to subcutaneous administration
of morphine and the intravenous antibiotic therapy
which were adjusted to the level of renal failure.
After hydration and intravenous infusions of glu-
cose with insulin, the concentration of creatinine
and potassium in the blood serum decreased. Dur-
ing her stay on the Palliative Care Ward, the patient
demonstrated deterioration in chronic renal disease
and in general clinical condition. The patient was
provided with the support of a psychologist and
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physiotherapist. The rehabilitation conducted on the
ward included passive exercises of the lower limbs,
active exercises of the upper limbs and breathing
exercises. When the patient's condition deteriorated
and muscle strength weakened, active exercises were
supported passively and finally only passive exercise
of the upper and lower limbs was carried out. Dur-
ing the stay on the Palliative Care Ward, the patient
experienced a pathological fracture of the right ra-
dial bone (Figures 1 and 2). A plaster splint was
applied after orthopaedic consultation. The patient
died due to anaemia and renal failure.
Discussion
Patients with multiple myeloma require concise
interdisciplinary cooperation during treatment. In
many cases, patients undergoing palliative care are
still treated with chemotherapy, which is connected
with frequent hospitalization and the necessity of
cooperation between the haematologist and the
palliative medicine specialist. The tasks of haema-
tologists include choosing the proper course of treat-
ment based on the results of additional tests and
the patient’s clinical condition. The palliative medi-
cine specialist who takes care of a patient with mul-
tiple myeloma will often have to deal with the long-
lasting complications of the treatment provided, as
well as the symptoms of the primary disease and its
secondary afflictions. Patients in this population suf-
fer from bone pain, often caused by pathological
fractures and their consequences (neurological dis-
orders). That is why they are often referred for pal-
liative care. At least 30% of such patients have fea-
tures of chronic renal disease, which will also devel-
op in a further 20–30%. As a result of osteolysis,
patients with multiple myeloma often have abnor-
mal plasma calcium values but hypercalcaemia may
remain unnoticed for a long time. Anaemia and
weakness are typical for almost all the patients. Doc-
tors during palliative care may also encounter bleed-
ing caused by hyperviscosity syndrome. The basic
form of treatment for multiple myeloma is chemo-
therapy, which most often allows for the achieve-
ment of a stable decrease of plasmocytes in the
marrow and of the concentration of M-protein in
blood serum and urine. It also decreases osteolytic
lesions. There are several schemes for cytostatic treat-
ment provided in cases of myeloma. The schemes
differ in respect to aggressiveness and the manner
of drug administration. If remission of the disease
occurs, long-lasting maintenance chemotherapy is
conducted [2, 3, 5, 6]. All the patients described
were provided with chemotherapy according to dif-
ferent schemes. In one case, thalidomide was ad-
ministered after the cytostatics with which the pa-
tient had been treated earlier proved to be non-
effective The drug suppresses angiogenesis of the
marrow microenvironment, induces apoptosis of
myeloma cells, and suppresses secretion of factors
that stimulate the development of neoplasm plas-
mocytes (IL-6, TNF). Thalidomide joined with dex-
amethasone (this combination is efficient in around
50% of patients) was administered to patient no. 5.
Although in various tests the analysis of the drug's
side-effects suggests it is safe, the patient experi-
enced high fever with chills and the blood culture
was positive for E.coli bacteria, which required tar-
geted antibiotic therapy [2, 4, 6, 7].
Infections were also observed in other analysed
patients. They took place either immediately after
chemotherapy or about 2 weeks after the treatment,
Figure 1. Osteolytic lesions in the course of multiple
myeloma, right prearm bone (patient no. 6)
Figure 2. Pathological fracture of right radial bone
(patient no. 6)
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when side-effects connected to the cardiovascular
system normally occur (leucopenia, neutropaenia,
granulocytopaenia, anaemia, thrombocytopaenia or
even pancytopaenia). They mostly concerned the
respiratory system and the otolaryngological zone.
Some patients required hospitalization. Patients with
myeloma are characterized by a significant deterio-
ration in immunity and, as a result, they are prone
to infections. If such infections occur, treatment with
antibiotics of a wide spectrum should always be
considered and started early. If granulocytopaenia
is diagnosed, it may be necessary to use factors
stimulating granulopoesis [2, 3, 6].
The most frequent symptom in this group of
patients is bone pain. It is estimated that it concerns
60–70% of patients. The pain is often acute, espe-
cially during movement and bone system ballasting.
It is most often connected to existent pathological
lesions in bones, being either a direct effect of the
disease or its secondary result (pathological frac-
tures). Treatment of pain in these patients is ex-
tremely difficult because it is associated with many
constraints. Usually in cases of bone pain, the first
choice drugs are NSAIDs. However, in patients with
myeloma benefits of administration of NSAIDs should
be carefully weighted against the risk of depressed
glomerular filtration rate (GFR) in some cases lead-
ing to renal failure. If we include opioids in pain
therapy, especially in cases of patients with myelo-
ma and coexistent chronic renal disease, the dosage
usually has to be adjusted to the level of renal fail-
ure. Most opioids used in therapy for chronic pain
with deterioration of renal functions should either
be administered in reduced dosages or the intervals
between doses should be prolonged. In end-stage
chronic renal disease, the maximum dose of trama-
dol should not exceed 50 mg twice a day [8]. In the
case of morphine metabolized in the liver and dis-
charged through the kidneys, active metabolites can
accumulate in patients with renal failure. The dos-
age of the opioid, therefore, has to be modified
according to GFR [9]. In this clinical case, it might be
advisable to consider the administration of renally
safer opioid, the elimination of which does not de-
pend on the kidneys to a great extent (methadone,
fentanyl or buprenorphine).
All the analysed patients were on NSAIDs. How-
ever, in the case of patient no. 1 the acetylsalicylic
acid was administered as prophylaxis for myocardial
infarction, not because of pain. When bleeding ap-
peared, due to the coexistence of thrombocytopae-
nia, the administration of the drug was discontin-
ued. Non-steroidal anti-inflammatory drugs were ad-
ministered to patient no. 6 only at the beginning of
hospital therapy and were rotated to opioids which
led to the pain relief. In the case of patient no. 2,
after stent implantation to the coronary artery ace-
tylsalicylic acid (and clopidogrel) were ordered due
to cardiological indications. In this case, a deteriora-
tion in renal functions took place immediately after
the contrast had been administered during coronar-
ography. We cannot exclude the negative influence
of NSAIDs on accelerating the process of renal func-
tion deterioration. NSAIDs were administered occa-
sionally to patient no. 5 with competent kidneys
and patient no. 3 still takes them occasionally.
Bone pain can be successfully treated with ra-
diotherapy and may be ameliorated by corticoster-
oids. Radiotherapy is also advisable in cases of
weight bearing bones which are threatened with
fracturing, especially around the spine, humerus
and femoral bone. None of the patients underwent
radiotherapy. Steroids, which might sometimes be
helpful were administered only in the case of pa-
tient no. 4.
For a better quality of life, it is important that
the patients remain physically active. Therefore, re-
habilitation in this group is a significant supplement
to the symptomatic treatment. It is essential that
the strategies for activating the patients are adjust-
ed to the particular phase of the disease and the
direct and indirect aims of the activity are estab-
lished. When constructing an activation programme
we should foresee complications of the disease or
its progress and we should act in order to minimize
their implications [10, 11]. In rehabilitation of pa-
tients with multiple myeloma, attention should be
paid especially to the necessity of stabilizing the
bones by orthopaedic equipment as a prophylaxis
for pathological fractures and protection against
spinal fractures. Corsets, laces and stabilization belts
should be used (as in the cases of patients no. 1 and
no. 3). Stabilization of the spine has to be carefully
considered when the patient is immobilized and
physical activity is constrained. The risk of patholog-
ical fractures is quite low at such patients (no load
on the movement system) and the stabilization it-
self disables the proper ventilation of the lungs
which, along with the long-lasting immobility and
often old age of the patients, significantly increases
the risk of complications in the respiratory system.
Stabilization in patients lying down may also con-
tribute to life's quality deterioration connected to
the process of applying the corset. That is why we
should consider the benefits and disadvantages of
a corset for such patients. Patient no. 6 was not
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provided with a corset due to the reasons described
above.
In the rehabilitation of patients with multiple
myeloma, we should also consider exercises which
are not too intensive. This helps to counteract the
effects of long-lasting immobility with the symp-
toms of joint dysfunctions, muscle weight loss, in-
creased risk of venous thrombosis, deterioration of
cardiorespiratory sufficiency, metabolic dysfunctions
and increased risk of decubitus ulcers [12]. This is
especially important in patients with neurological
lesions during the course of spinal cord compres-
sion syndrome. Proper physiotherapy allows the
maintenance of the appropriate length of muscles,
which significantly facilitates patient care.
In walking patients, attention has to be paid to
safety of movement and the possibility of providing
the patient with crutches, a cane or zimmerframe.
Rehabilitation of patients with multiple myelo-
ma has to be conducted in accordance to the basic
rule of improving in functioning and quality of life
in palliative care, formed by Fulton and Else, which
says that it should be carried out: “often but in
small doses” [13]. The exercises cannot be too in-
tensive and they cannot cause an escalation of pain.
A single therapeutic session should not last too long
but should be repeated 2–3 times a day. It is, there-
fore, extremely important to engage the family in
patient care. This also allows for continuing rehabil-
itation at home, according to instructions provided
by the therapist.
In order to optimize the quality of life of the
patients, proper orthopaedic treatment in accor-
dance with bone lesions is essential. As prophylax-
is, we should also consider stabilization of the long
bones with the use of intramedullar wire fixation
to prevent fractures and secondary pain syndromes.
Vertebral fractures are usually accompanied by se-
vere pain and often require surgery. This pain is
often only partly responsive to opioids. If it is con-
nected with a lesion of the nervous structures and
neuropathic pain is diagnosed, then it is necessary
to administer coanalgetics [1–3, 6, 14]. In the case
of patient no. 3, percutaneous vertebroplasty di-
minished the pain almost totally. The patient re-
quired only small doses of weak opioids (tramad-
ol) and a Jawett corset. In the case of patent no. 1
(with a vertebral fracture of L2), the surgeons with-
drew from the planned operation due to the de-
crease of pain and advised a Jewett corset. Pa-
tient no. 6 had a pathological fracture of the right
radial bone, which was orthopaedically protected
(Figures 1 and 2).
Pathological lesions of the spine may lead to
spinal cord compression. Therefore, sudden neuro-
logical syndromes in the lower limbs and pain esca-
lation require immediate diagnosis. Apart from spi-
nal cord compression, nerve roots may also be com-
pressed. It is important to establish diagnosis be-
fore irreversible neurological lesions appear (left side
paralysis) and to implement an appropriate course
of treatment (local radiotherapy or operation). In
the case of any suspicion of spinal cord or nerve
root compression, large doses of steroids should be
administered until diagnosis and the establishment
of a therapy plan [1, 2, 6, 14].
Delayed diagnosis and significant local develop-
ment of lesions around the spine and chest in the
case of patient no. 6 made neurological treatment
impossible. Patient no. 4, apart from spinal pains,
had left leg aesthesia disorders with coexistent mus-
cular atrophy and debility of muscle strength.
In patients with neoplastic metastasis to the
bones, bisphosphonates are especially important.
Their administration prevents the appearance of skel-
etal-related events, helps to ease bone pain and
improve the quality of life. Results of randomized
trials confirmed the efficacy of these drugs in bone
complications in patients with myeloma [2, 3, 15,
16]. American Society of Clinical Oncology (ASCO)
established guidelines connected to the appropri-
ate choice of bisphosphonate and indications for its
administration [17]. In the case of multiple myelo-
ma with osteolytic lesions in radiological test, it sug-
gests administering pamidronate by intravenous in-
fusion in a dose of 90 mg or zoledronate 4 mg every
3–4 weeks (with dose adjustment according to re-
nal function) until the clinical efficacy of the drug is
exhausted [17]. The risk of renal toxicity is reduced
by adhering to the recommended dose and infusion
rate, ensuring adequate hydration, monitoring re-
nal function and adjusting the dose as appropriate
or discontinuing treatment if there is deterioration,
and avoiding the concurrent use of other nephro-
toxic drugs. Both drugs are advised for the therapy
of pain caused by osteolytic lesions and following
radiotherapy, after operational procedures of spinal
stabilization in patients who take typical analgesics
in pain therapy [17]. Among the analyzed patients,
bisphosphonates were administered to all (intrave-
nous infusions were provided to 2 patients during
the therapy).
Another difficulty in the treatment of patients
with multiple myeloma is connected to chronic re-
nal disease resulting from nephropathy that is se-
condary to myeloma or coexistent renal disease of
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another type. At the moment of diagnosis, 30% of
patients already suffer from chronic renal disease,
in 50% it will develop and 20% suffer from signifi-
cant renal failure, which is irreversible despite hy-
dration and diuresis. Simultaneous diagnosis of de-
veloped chronic renal disease and multiple myelo-
ma concerns 12% of patients. Nephrologists qualify
patients for haemodialysis in the 5th stage of chronic
renal disease. It is assumed that the performance of
chronic haemodialysis in patients with myeloma with
coexistent developed chronic renal disease provides
the possibility of prolonging a patient’s life by 17–
–20 months. It is assumed that 20% of patients die
during the first month, with one-third living a fur-
ther 3–5 years. However, half of the patients with
diagnosed chronic renal disease are expected to im-
prove their condition between the 30th and 70th day
of the appropriate treatment. That is why hydration
is especially important in these patients, especially
in those with diagnosed chronic renal disease prior
to chemotherapy.
Intravenous infusions of 0.9% NaCl are suggest-
ed before treatment with cystostatics in order to
achieve diuresis of 2–3 litres a day. It is important to
prevent urine acidaemia and, because of this, oxy-
dasis inhibitors are administered (the best is allopu-
rinol) before chemotherapy. If the patient has been
diagnosed as suffering from chronic renal disease, it
is difficult to select an appropriate cystostatic treat-
ment, especially when establishing an effective but
non-toxic dose of melphalan. Instead of MP, it is
more beneficial to administer only corticosteroids
or multi-drug schemes which do not include mel-
phalan. In patients with a high concentration of M-
protein in the blood serum, we may perform plas-
mapheresis (as in patient 2) [2, 3, 6, 18, 19].
Multiple myeloma also frequently involves hy-
percalcaemia. Its early symptoms (drowsiness, loss
of muscle strength, depression, moderate abdomi-
nal pain, constipation and loss of appetite) can re-
main unnoticed. Nausea (even severe), dementia and
mood changes may also appear. The basis of hyper-
calcaemia treatment is intravenous administration
of bisphosphonate. Improvement of diuresis with
furosemide and the administration of steroids may
also be helpful. In reoccurrence of hypercalcaemia,
it may be necessary to administer calcitonin, espe-
cially in patients with chronic renal disease, where it
is necessary to avoid bisphosphonates due to in-
creased levels of creatinine and phosphates [6, 14,
18–21]. In two of the described patients, only a
temporary increase of plasma calcium concentra-
tion was observed (patients no. 1 and no. 4).
Multiple myeloma as one of fast proliferating
neoplasms is associated with the risk of acute tumor
lysis syndrome (ATLS). Rapid disintegration of cells
during chemotherapy causes a sudden secretion of
large quantities of potassium, phosphates and nu-
cleic acids metabolized into uric acid. Secondly, re-
nal dysfunctions appear, especially if the process is
accompanied by dehydration [20].
All the observed patients had secondary anaemia
(during the course of the basic disease, after che-
motherapy, or secondarily to chronic renal disease).
This required a transfusion of red blood cells in some
of the patients during each planned hospitalization.
In patients with myeloma, the administration of an-
drogens or erythropoetin may be beneficial in order
to induce erythropoiesis. The increase of haemoglo-
bin concentration during the subcutaneous admin-
istration of erythropoietin can be observed after
a few weeks and discontinuation of this therapy
causes a relapse of anaemia [2, 3, 6]. In the ob-
served patients erythropoietin was not administered.
Some of the patients may exhibit symptoms of
hyperviscosity syndrome connected to a high con-
centration of M-protein. In the case of patient no. 1,
frequent bleeding from the nose and mucous mem-
branes of the mouth as well as from the anus was
observed. They twice became a reason for emergen-
cy hospitalization. There were haematoceles on the
patient's skin. The patient was administered with
antihaemorrhagic drugs, strengthening and tight-
ening the endothelium of the blood vessels. In the
treatment of hyperviscosity syndrome we may use
cystostatics, large dosages of corticosteroids and
perform plasmapheresis.
In the case of patient no. 5, elevated body tem-
perature was observed, along with temporary fever
with no visible source of infection. The patient also
reported increased perspiration, which could be part-
ly explained by the subfebrile conditions. The pa-
tient was treated with paracetamol and NSAIDs.
Patients with multiple myeloma are a great chal-
lenge in palliative care due to the highly change-
able clinical course of the disease, repetitive relaps-
es and remissions. Numerous and often secondary
coexistent symptoms require constant control and
the appropriate treatment, and demonstrate that
simultaneous multi-specialist care based on the col-
laboration of doctors from different specialties and
cooperation between the patient's home and the
hospital are essential. Patients with multiple my-
eloma require constant therapy according to the
specificity of the particular stage of the disease.
Apart from the chemotherapy, special attention
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should be paid to the renal function, anaemia re-
quiring blood transfusion, and frequent infections,
which often require antibiotic therapy. Administra-
tion of bisphosphonates may reduce the incidents
of hypercalcaemia and simultaneously support
treatment of bone pain.
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